EARNEST Partners’s United Therapeutics UTHR Stock Holding History

EARNEST Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-113	Closed	-$25.5K	–	1052
2023 Q3	$25.5K	Hold	113	–	–	﹤0.01%	451
2023 Q2	$24.9K	Hold	113	–	–	﹤0.01%	444
2023 Q1	$25.3K	Hold	113	–	–	﹤0.01%	432
2022 Q4	$31.4K	Hold	113	–	–	﹤0.01%	396
2022 Q3	$24K	Hold	113	–	–	﹤0.01%	421
2022 Q2	$27K	Buy	113 +100	+769%	+$20.3K	﹤0.01%	407
2022 Q1	$2K	Hold	13	–	–	﹤0.01%	1050
2021 Q4	$3K	Hold	13	–	–	﹤0.01%	986
2021 Q3	$2K	Hold	13	–	–	﹤0.01%	1059
2021 Q2	$2K	Hold	13	–	–	﹤0.01%	1064
2021 Q1	$2K	Hold	13	–	–	﹤0.01%	1071
2020 Q4	$2K	Hold	13	–	–	﹤0.01%	1047
2020 Q3	$1K	Hold	13	–	–	﹤0.01%	1120
2020 Q2	$2K	Hold	13	–	–	﹤0.01%	975
2020 Q1	$1K	Hold	13	–	–	﹤0.01%	1061
2019 Q4	$1K	Hold	13	–	–	﹤0.01%	1137
2019 Q3	$1K	Hold	13	–	–	﹤0.01%	1126
2019 Q2	$1K	Hold	13	–	–	﹤0.01%	1141
2019 Q1	$2K	Hold	13	–	–	﹤0.01%	1043
2018 Q4	$1K	Hold	13	–	–	﹤0.01%	1137
2018 Q3	$2K	Hold	13	–	–	﹤0.01%	1052
2018 Q2	$1K	Hold	13	–	–	﹤0.01%	1155
2018 Q1	$1K	Hold	13	–	–	﹤0.01%	1143
2017 Q4	$2K	Buy	+13	New	+$1.65K	﹤0.01%	1028
2017 Q1	–	Sell	-13	Closed	-$2K	–	873
2016 Q4	$2K	Buy	+13	New	+$1.66K	﹤0.01%	969

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

EARNEST Partners's UTHR Position: Q4 2023 in Review

EARNEST Partners sold out of United Therapeutics (UTHR) in Q4 2023, closing a stake of 113 shares — an estimated $25.5K sold.

EARNEST Partners first reported a position in UTHR in Q4 2016 and held it in 25 quarters. The position peaked at $31.4K in Q4 2022. 535 funds tracked by Wall St. Rank hold UTHR as of Q4 2023.

EARNEST Partners reported no remaining United Therapeutics position as of Q4 2023 after selling out during the quarter.
EARNEST Partners sold 113 United Therapeutics shares in Q4 2023, an estimated $25.5K.
EARNEST Partners first reported a position in United Therapeutics in Q4 2016 and held it in 25 quarters.
EARNEST Partners's United Therapeutics position peaked at $31.4K in Q4 2022.
535 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2023.

Based on EARNEST Partners's 13F filing for Q4 2023, filed 14 Feb 2024.